Waters stock price target raised to $375 from $350 at BofA Securities

Investing.comTuesday, November 4, 2025 at 9:33:02 PM
Waters stock price target raised to $375 from $350 at BofA Securities
BofA Securities has raised its price target for Waters Corporation's stock from $350 to $375, reflecting a positive outlook on the company's performance.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Palantir Raises Outlook, But Valuation Concerns Grow
PositiveFinancial Markets
Palantir's outlook has been raised by BofA Securities Analyst Mariana Perez Mora, who believes the company will thrive even if the AI bubble bursts. She shared insights on Palantir's strong earnings and its unique position in the AI sector during a discussion with Caroline Hyde and Ed Ludlow on Bloomberg Tech.
BofA Securities downgrades Eurocommercial Properties stock to Neutral
NegativeFinancial Markets
BofA Securities has downgraded Eurocommercial Properties stock to a neutral rating, signaling a cautious outlook for investors. This decision reflects concerns about the company's performance in the current market environment, which could impact investor confidence and stock value. It's important for stakeholders to stay informed about such changes as they can influence investment strategies and market dynamics.
Palantir stock price target raised to $255 from $215 at BofA Securities
PositiveFinancial Markets
Palantir Technologies has received a significant boost as BofA Securities raised its stock price target from $215 to $255. This adjustment reflects growing confidence in Palantir's business model and future prospects, which is crucial for investors looking for promising opportunities in the tech sector. The increase in target price indicates that analysts believe the company is on a strong upward trajectory, making it an exciting time for stakeholders.
BofA Securities raises AerCap stock price target to $150 on supply constraints
PositiveFinancial Markets
BofA Securities has raised its price target for AerCap's stock to $150, citing supply constraints as a key factor. This adjustment reflects confidence in AerCap's ability to navigate current market challenges, which is significant for investors looking for stability in the aviation sector. The increase in the price target suggests that analysts believe AerCap is well-positioned for growth despite ongoing supply issues.
BofA Securities upgrades Unibail-Rodamco-Westfield stock to Buy on growth outlook
PositiveFinancial Markets
BofA Securities has upgraded Unibail-Rodamco-Westfield's stock to a 'Buy' rating, citing a strong growth outlook for the company. This upgrade is significant as it reflects confidence in the company's future performance, potentially attracting more investors and boosting stock prices. Such positive assessments can lead to increased market interest and may enhance the company's ability to raise capital for future projects.
Latest from Financial Markets
Private-Credit Earnings Ease Investor Concern Over Asset Class’s Health
PositiveFinancial Markets
Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the stability of the sector.
Private-Credit Earnings Ease Investor Concern Over Asset Class’s Health
PositiveFinancial Markets
Apollo CEO Marc Rowan has reassured investors by addressing concerns regarding the health of the private-credit asset class, easing worries and highlighting the sector's resilience.
Aviat Networks Q1 FY2026 slides: Revenue jumps 21.4%, exceeding expectations
PositiveFinancial Markets
Aviat Networks reported a remarkable 21.4% increase in revenue for Q1 FY2026, surpassing market expectations. This growth highlights the company's strong performance and positive outlook in the telecommunications sector.
Stoke Therapeutics Q3 2025 presentation: strong revenue growth amid clinical progress
PositiveFinancial Markets
Stoke Therapeutics recently presented its Q3 2025 results, showcasing impressive revenue growth alongside significant advancements in its clinical programs. The company's progress highlights its commitment to developing innovative therapies, making it a key player in the biotechnology sector.
Amgen Q3 2025 slides: Revenue up 12%, guidance raised on strong product performance
PositiveFinancial Markets
Amgen has reported a 12% increase in revenue for Q3 2025, prompting the company to raise its guidance due to strong product performance. This positive trend highlights the effectiveness of their strategies and the growing demand for their offerings.
Corsair Q3 2025 slides show strong growth amid missed earnings forecasts
NeutralFinancial Markets
Corsair's Q3 2025 slides indicate a strong growth trajectory, despite missing earnings forecasts. The company is navigating challenges while showcasing resilience in its performance.